Work

EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis

Year: 2021

Type: article

Source: International Journal of Gynecological Cancer

DOI: 10.1136/ijgc-2021-igcs.199

Authors: N. Upadhyay, L. Ralph, C. Ljungcrantz, A. Merchant, B. Haycroft, A. Fornwall, V. Prabhu, R. Orlowski, L. Duska

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), BresMed, MSD (Sweden), Quantify Research (Sweden), University of Virginia

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3209817601

FWCI:

Cites:

Cited by:

Related to: 10